Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study

Launched by UNIVERSITY MEDICAL CENTRE LJUBLJANA · Jun 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a medicine called Cerebrolysin can help people recover better after having an ischemic stroke, which is a type of stroke caused by a blocked blood vessel in the brain. The study focuses on patients who have moderate difficulties with movement or thinking right after their stroke and are starting rehabilitation, which is therapy to help improve their abilities. Researchers want to see if giving Cerebrolysin during this early recovery phase is safe and if it helps patients regain their functions more effectively.

People who may join the study are adults who recently had an ischemic stroke confirmed by brain scans, and who have a moderate level of neurological problems as measured by a standard test (NIHSS score between 6 and 12). They should not have had any previous strokes or disabilities before this event and must be able to complete a specific test of arm and hand movement (called the ARAT test). Participants will be asked to give their consent to join and must be able to understand instructions. If accepted, they will receive treatment with Cerebrolysin as part of their early rehabilitation, and doctors will monitor their progress and any side effects. This trial is currently recruiting patients and welcomes adults of all genders between 65 and 74 years old.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Being able to perform ARAT test Signed informed consent
• • Both sexes, age not specified
• • Acute ischemic stroke confirmed by imaging
• • NIHSS score 6-12
• • No prior stroke or disability (mRS 0 before stroke)
• • -
• Exclusion Criteria:
• • Not being able to perform ARAT test
• • Previous stroke or disability (mRS \> 0)
• • The patient unable to understand instructions